FDA Clearance Buzz: Recent chatter on X about SINTX Technologies has centered on the FDA clearance of their SINAPTIC® Foot & Ankle Implant System in October 2025. Many users are highlighting this as a significant step, opening doors to a billion-dollar U.S. market. The excitement is palpable as discussions focus on potential growth from this milestone.
Evonik Deal Sparks Interest: Another hot topic on X is the recent supply agreement with Evonik for AI-assisted 3D-printed implants, announced in late November 2025. Posts reflect optimism about immediate production capabilities for specialized implants in trauma and oncology. This partnership is seen as a boost to SINT’s innovation edge.
Financial Updates in Focus: X discussions also touch on SINTX’s Q3 2025 financials, with some noting a sharp revenue drop of 74% year-over-year and ongoing net losses. Despite this, a few users point to FDA progress and cost reductions as reasons for hope. The mixed financial picture keeps the conversation dynamic and divided.
Note: This discussion summary was generated from an AI condensation of post data.
SINTX Technologies Insider Trading Activity
SINTX Technologies insiders have traded $SINT stock on the open market 32 times in the past 6 months. Of those trades, 32 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $SINT stock by insiders over the last 6 months:
- GREGG R. HONIGBLUM (Chief Investment Officer) has made 25 purchases buying 125,000 shares for an estimated $472,250 and 0 sales.
- ERIC K. OLSON (President and CEO) has made 5 purchases buying 16,275 shares for an estimated $57,190 and 0 sales.
- MARK LEWIS ANDERSON purchased 10,000 shares for an estimated $33,000
- JAY M MOYES purchased 3,000 shares for an estimated $10,756
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
SINTX Technologies Revenue
SINTX Technologies had revenues of $208K in Q3 2025. This is a decrease of -73.97% from the same period in the prior year.
You can track SINT financials on Quiver Quantitative's SINT stock page.
SINTX Technologies Hedge Fund Activity
We have seen 13 institutional investors add shares of SINTX Technologies stock to their portfolio, and 6 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DRW SECURITIES, LLC added 110,354 shares (+inf%) to their portfolio in Q3 2025, for an estimated $451,347
- VIRTUS WEALTH SOLUTIONS LLC added 94,928 shares (+inf%) to their portfolio in Q3 2025, for an estimated $388,255
- HEIGHTS CAPITAL MANAGEMENT, INC removed 60,964 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $196,304
- RENAISSANCE TECHNOLOGIES LLC added 27,552 shares (+inf%) to their portfolio in Q3 2025, for an estimated $112,687
- CITADEL ADVISORS LLC removed 21,620 shares (-61.6%) from their portfolio in Q3 2025, for an estimated $88,425
- HRT FINANCIAL LP added 18,311 shares (+inf%) to their portfolio in Q3 2025, for an estimated $74,891
- BROADWAY WEALTH SOLUTIONS, INC. added 15,000 shares (+inf%) to their portfolio in Q3 2025, for an estimated $61,350
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
SINTX Technologies Analyst Ratings
Wall Street analysts have issued reports on $SINT in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Ascendiant Capital issued a "Buy" rating on 12/08/2025
To track analyst ratings and price targets for SINTX Technologies, check out Quiver Quantitative's $SINT forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
